Sign in

CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

enGene Therapeutics Inc.

Sign in to watch
Ticker
ENGN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Oct 31
Incorporated
Canada (Federal Level)
Entity type
operating
Phone
(514) 332-4888
Business address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
Former names
enGene Holdings Inc.

Securities

  • ENGN Common Stock Nasdaq
  • ENGNW Warrants Nasdaq
  1. 8-K Event Results of operations · Regulation FD disclosure · Other events
  2. 4 Open-market buy Interim Chief Medical Officer bought 5,102 shares at $1.97 ($10,051)
  3. 10-Q Report Quarterly Report
  4. 8-K Event Results of operations
  5. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  6. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  7. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  8. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  9. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  10. 8-K Event Other events
  11. 3 Insider Initial Statement of Ownership
  12. 3 Insider Initial Statement of Ownership
  13. SCHEDULE 13G Stake Statement of Beneficial Ownership
  14. 8-K Event Regulation FD disclosure
  15. 8-K Event Executive or director change · Regulation FD disclosure
  16. 8-K/A Event Exit or restructuring costs · Executive or director change
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 1 of 14 · 268 filings